




Broadening the debate about post-trial access to medical interventions: a 
qualitative study of participant experiences at the end of a trial investigating a 
medical device to support type 1 diabetes self-management 
 
J Lawton1, M Blackburn1, D Rankin1, C Werner1, C Farrington2, R Hovorka3,4, N 
Hallowell5  
 
1Usher Institute of Population Health Sciences and Informatics, University of 
Edinburgh, Edinburgh, UK  
2Cambridge Centre for Health Services Research, University of Cambridge, UK 
3Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, 
Cambridge, UK  
4Department of Paediatrics, University of Cambridge, Cambridge, UK 
5Wellcome Centre for Ethics and Humanities and the Ethox Centre, Nuffield 
Department of Population Health, Big Data Institute, University of Oxford, UK 
 
Corresponding author: Julia Lawton (J.Lawton@ed.ac.uk) 
 
   
2 
 
Broadening the debate about post-trial access to medical interventions: a 
qualitative study of participant experiences at the end of a trial investigating a 
medical device to support type 1 diabetes self-management 
 
Abstract 
Increasing ethical attention and debate is focusing on whether individuals who take 
part in clinical trials should be given access to post-trial care. However, the main 
focus of this debate has been upon drugs trials undertaken in low income settings.  
To broaden this debate, we report findings from interviews with individuals (n=24) 
who participated in a clinical trial of a closed-loop system, which is a medical device 
under development for people with type 1 diabetes which automatically adjusts blood 
glucose to help keep it within clinically recommended ranges. Individuals were 
recruited from UK sites and interviewed following trial close-out at which point the 
closed-loop had been withdrawn. While individuals were stoical and accepting of the 
requirement to return the closed-loop, they also conveyed varying degrees of 
distress. Many described having relaxed diabetes management practices while using 
the closed-loop and having become deskilled as a consequence which made 
reverting back to pre-trial regimens challenging. Participants also described 
unanticipated consequences arising from using a closed-loop. As well as deskilling, 
these included experiencing psychological and emotional benefits which could not be 
sustained after the closed-loop had been withdrawn; and, participants re-evaluating 
their pre- and post-trial life in light of having used a closed-loop and now perceiving 
this life much more negatively. Participants also voiced frustrations about 
experiencing better blood glucose control using a closed-loop and then having to 
revert to using what they now saw as antiquated and imprecise self-management 
3 
 
tools. We use these findings to argue that ethical debates about post-trial 
provisioning need to be broadened to consider potential psychological and emotional 
harms, and not just clinical harms, which may result from withdrawal of investigated 
treatments. We also suggest that individuals may benefit from information about 
potential non-clinical harms to help make informed decisions about trial participation. 
 






Clinical trials rely on volunteers who should not experience unnecessary harm as a 
result of their participation. Hence, regulations and codes of practice have been put 
in place to help ensure research designs are rigorous and appropriate, that risks 
associated with participation are minimised, that individuals are able to make 
informed and voluntary decisions about taking part and that research participants are 
treated with dignity and respect (Grady 2005; Emanuel et al. 2000). Until relatively 
recently it has been assumed that the trial team’s ethical, legal and clinical 
responsibilities to participants stop when a trial comes to an end (Cook, Snyder, and 
Calvert 2016; Grady 2005). However, increasing attention and debate is focusing on 
whether individuals should be given access to post-trial care (Cook, Snyder, and 
Calvert 2016; Doval, Shirali, and Sinha 2015; Merritt and Grady 2006; Usharani and 
Naqvi 2013; El Setouhy et al. 2002; Pratt and Loff 2011). This attention has been 
prompted by the globalization of clinical trial research and, more specifically, the 
growing involvement of individuals from low income settings in pharmaceutical trials 
(Cook, Snyder, and Calvert 2016; Petryna 2009). Particular concern has been 
expressed about the ethics of allowing such individuals to shoulder the risks and 
burdens of trial participation when the beneficiaries tend to be companies and 
individuals in the developed world (Cook, Snyder, and Calvert 2016; Millum 2011; 
Macklin 2004). To avoid potential exploitation, and fulfil an ethic of beneficence and 
reciprocity, it has been argued that there is a moral and ethical imperative to give 
individuals, who could not otherwise afford them, ongoing access to trial (drug) 
treatments if these are shown to be effective (Cook, Snyder, and Calvert 2016; 
Milllum 2011). Such an imperative is seen to be heightened in situations where 
withdrawal of drug therapy might result in the worsening of an individual’s condition, 
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or possibly even death (Doval, Shirali, and Sinha 2015; Grady 2005) and, hence, 
where the basic tenant of human dignity might be violated (Andanda and Wathuta 
2017). 
 
Indeed, it was in response to the above kinds of concerns that, in 2000, the 
Declaration of Helsinki mandated that: “at the conclusion of the study, every patient 
entered into the study should be assured of access to the best proven prophylactic, 
diagnostic and therapeutic methods identified by the study” (World Medical 
Association 2000, 3045). Similar recommendations for post -trial access to products 
and procedures of proven efficacy have also been made by other organizations (e.g., 
WHO and CIOMS 2016; UNAIDS 2011). While these kinds of guidelines have been 
welcomed, concern has also been expressed about the ethics of providing post-trial 
treatment to individuals if this means depriving those who have greater clinical need 
(Usharani and Naqvi 2013). Hence, some commentators have proposed that a fair-
benefits framework be adopted, wherein research teams work in collaborative 
partnership with target populations in developing communities and allow these 
communities to decide how the benefits of the research are distributed (El Setouhy 
et al 2002). In such cases, a fair benefit might not simply be on-going access to the 
investigated treatment; it could also be achieved through other means, such as 
investment in the local health infrastructure (Ballyantyne 2008; El Setouhy et al. 
2002). It has, however, also been noted that a requirement to offer post-trial care (or 
equivalent investment in the host community) will escalate the costs of research and 
mean less trials are conducted. Hence, commentators have observed that the ethics 
of providing post-trial access is far from straightforward (Doval, Shirali, and Sinha 




To date, ethical attention and debate has overwhelmingly focused on trials 
undertaken in low income settings and drugs trials in particular (Cook, Snyder, and 
Calvert 2016; Sofaer and Stretch 2011). As some commentators have noted, this 
has potentially meant that participants’ need for medical interventions at the end of 
other kinds of trials, including those undertaken in high income settings, might have 
been side-lined (Andanda and Wathuta 2017; Millum 2011; Soafaer et al. 2009); 
albeit others have argued that trial research undertaken in high income settings is 
likely to be less ethically contentious. This is because, if a trialled intervention is 
shown to be efficacious, there is a high probability that it will be introduced into the 
health care system and, hence, made available to at least some citizens (Pratt and 
Loff 2011) 
 
It is noteworthy that, despite the emphasis placed on treating trial participants in fair 
and ethical ways, these individuals have rarely been consulted about the care and 
support they feel they need at the end of a trial. In rare instances where consultation 
has taken place, drugs trials have been the focus of the research, with participants 
generally endorsing post-trial drug provisioning, especially when individuals might 
otherwise be unable to afford treatments (Pace et al. 2006; Shaffer et al. 2006). 
Currently missing from the literature is consideration of what should happen at the 
end of trials involving withdrawal of technologies/medical devices rather than drugs, 
where distinctive ethical challenges might arise and specific considerations may be 
needed to help address these. Arguably, this kind of work is both pressing and timely 
given that trials of medical devices are becoming increasingly common and 
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widespread, especially in the field of diabetes research (Bekairi et al. 2018; Poolsup, 
Suksomboon and Kyaw 2013). 
 
To address a lacunae in the literature and expand, and potentially advance, debates 
about post-trial provisioning, we report findings from a qualitative study involving 
individuals who took part in an open-label, multi-centre, randomized trial which sought 
to test the safety and efficacy of a closed loop system as compared to sensor 
augmented pump therapy (an open-loop system which is commercially available) in 
adults and youth (aged 6 years and over) who had type 1 diabetes. A closed-loop 
system is a medical device under development for people who have type 1 diabetes 
which is a chronic disease which occurs when the pancreas is unable to produce 
insulin. Hence, individuals affected by this condition have to self-regulate their blood 
glucose and try to keep it within the ‘normal’ range in order to remain healthy. This is 
because high blood glucose levels increase the risk of long-term complications (e.g., 
blindness, amputation and stroke), whereas low blood glucose (hypoglycemia) can 
lead to confusion, seizures, periods of unconsciousness and sometimes even death. 
Individuals normally regulate their (or their child’s) blood glucose by administering 
insulin (via injections or an insulin pump) and calculating and titrating doses according 
to the results of blood glucose checks (normally finger prick tests undertaken 5-6 times 
daily), food consumed, physical activity and other factors (e.g. illness). The closed-
loop system investigated in the trial comprised an insulin pump, a continuous glucose 
monitoring (CGM) device which measured interstitial blood glucose every 5 mins, and 
a computer-based algorithm which translated, in real-time, the information received 
from the CGM device, in order to determine the amount of insulin which was then 
automatically delivered by the pump. As well as improving an individual’s blood 
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glucose control, an intended purpose of closed-loop technology is to reduce the 
burden of self-management (Bekiari et al. 2018), albeit users of the specific closed-
loop system investigated in the trial had to determine the amount of carbohydrates 
they consumed in meals/snacks and enter this information so that an appropriate 
amount of extra insulin could be administered by the closed-loop (Bally et al. 2017). 
 
The trial was conducted in UK sites and used a 1:1 randomization procedure. To be 
eligible for the trial, individuals needed to have been using an insulin pump for at least 
three months and to have had sub-optimal blood glucose control (Bally et al. 2017). 
During the trial, participants attended up to 11 in-clinic visits and had six pre-planned 
telephone contacts (Bally et al. 2017). Following trial completion, individuals were put 
back on to their pre-trial (i.e. insulin pump) regimen – this meant that, in practice they 
had to stop using the CGM device and algorithm which automatically regulated their 
or their child’s blood glucose. In the participant information sheet, participants were 
advised of the requirement to return the study devices promptly at the end of the study 
and that, as a last resort, the trial team would use legal measures to ensure this 
happened. Participants were also advised of possible risks arising from study 
participation, such as a low risk of hyperglycaemia leading to diabetic ketoacidosis 
resulting from use of the closed-loop; however, the participant information sheet made 
no mention of any possible risks resulting from withdrawal of the closed-loop at the 
end of the study period.  
 
In many respects, the study reported here is an unusual example as it drew upon the 
perspectives and experiences of participants who had participated a trial of a 
medical device (rather than a drug) which had to be withdrawn at the end as it was 
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still under development and, hence, not yet licensed for clinical use. However, while 
commentators have suggested that Phase I-III trials are relatively uncontroversial 
because “no efficacious product can be expected at the end of such trials in order to 
fulfil any post-trial obligation of making the product available to participants” 
(Andanda and Wathuta 2017) (unless a country’s regulations permit a 
compassionate use exemption to be exercised), we will show that ethical and other 
considerations nonetheless exist when an investigated treatment is not available 
post-trial.  
 
The material reported here forms part of a broader qualitative study in which we 
interviewed participants following randomization to a closed-loop and within 1-2 
weeks of completing the three month trial, at which point they had returned the 
closed-loop to the trial team. The main purpose of this qualitative research was to 
explore people’s initial understandings and expectations of closed-loop systems, 
their likes and dislikes of using a closed-loop and their views about how the 
technology might be improved to increase efficacy and acceptability for future users 
(findings from this component of the research are reported separately - references 
removed for blinding purposes). However, after initial end of trial interviews alerted 
us to participants experiencing anxiety and distress as a result of having to return the 
close-loop, a decision was made to add a bioethical expert to the qualitative 
research team and broaden the remit of these interviews. Specifically, we used these 
interviews to understand and explore the reasons for participant distress, and what, 
from their perspectives, might be done differently to support people who take part in 
future trials which require medical devices to be returned at the end of the study 
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period. It is the findings from these aspects of the interviews which form the focus of 
our reporting here.   
 
Methods 
In-depth interviews informed by topic guides were used so that the discussion 
remained relevant to the study aims, while affording the flexibility needed for 
participants to raise and discuss issues they perceived as salient, including those 
unforeseen at the study’s outset (Pope and Mays 1995). An inductive approach was 
used (Strauss and Corbin 1990) in which data collection and analysis took place 
concurrently allowing findings from early interviews to iteratively inform areas 
explored in later ones; for instance, as indicated above, our decision to broaden the 
remit of the end of trial interviews to understand and explore participants’ reactions 
to withdrawal of the closed-loop in more depth.  
 
Sample and recruitment 
We interviewed adult (18+ years) and adolescent (13-17 years) trial participants and 
parents of trial participants aged 13-15 years and 12 years and under. The decision 
to interview parents was made because, amongst pre-teenage children, parents take 
overarching responsibility for diabetes management tasks and decision-making 
(Lawton et al. 2015) and, hence, it was recognised that these individuals would have 
primary responsibility for using the closed-loop. We also decided to interview parents 
of trial participants aged 13-15 years as, in the early teenage years, youth often 
continue to look to their parents for input and support when undertaking diabetes 




Participants were recruited and consented into the qualitative research at the same 
time as they were recruited into the trial. Recruitment was undertaken by members 
of the clinical team in all four participating UK trial sites using an opt-in procedure, 
with assent procedures used for minors (Bally et al. 2017). Data collection for the 
qualitative research continued until data saturation was reached; that is, until no new 
findings were identified in new data collected. 
 
Data collection and analysis 
[Name removed] conducted the interviews at a time and location of participants’ 
choosing, using a topic guide which was developed in light of literature reviews, input 
from the co-investigator team and revised in light of emerging findings (see above). 
Key areas explored which are relevant to the reporting in this paper include: 
perceptions and understandings of the trial; experiences of undertaking diabetes 
(self-) management using a closed-loop; perceived impact of using a closed-loop on 
oneself and others, food choices and eating practices, (physical) activity and 
everyday (work, school, family) life; benefits and burdens of using a closed-loop as 
compared to pre-trial regimens; experiences of trial close-out; reactions to 
withdrawal of the closed-loop (and participants’ own understandings of the reasons 
for these); views about how close-out experiences could be improved for future trial 
participants; and, participants’ information and support needs post-trial. 
 
Interviews took place between October 2016 and August 2017. These typically 
lasted 1-2 hours, were digitally recorded and transcribed in full. Data were analysed 
by a team of experienced qualitative researchers [Names removed] using a thematic 
approach involving cross-comparison of all interviews to identify recurrent themes 
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(Strauss and Corbin 1990). These researchers undertook initial analyses 
independently and wrote separate reports before meeting to discuss their 
interpretations and reach agreement on key findings and themes. A coding frame 
was then developed which captured these findings and themes. Nvivo Version 10 
(QSR International Pty Ltd., Doncaster, Victoria, Australia), a qualitative software 
package, was used to facilitate data coding and retrieval and coded datasets were 
subjected to further analyses to allow more nuanced interpretations of the data to be 
developed and identify sub-themes and illustrative quotations.  
 
The <trial name deleted for peer review> and qualitative study received approval 
from <institutional name and REC number deleted for peer review>. To safeguard 
anonymity, unique identifiers are used in the reporting of data below. 
 
Results 
N=24 participants, comprising 10 adults (aged 18+ years), 5 adolescents (aged 13-
17 years) and 9 parents were interviewed. Demographic details are presented in 
Table 1.  
 
[Table 1 about here] 
 
Participants, in their post-trial interviews, described having being stoical and 
accepting of the requirement to return the closed-loop at the end of the 3 month 
study period. However, while none expressed anger or resentment, and virtually all 
conveyed enthusiasm for taking part in further trials, participants in all groups also 
conveyed varying degrees of upset and distress. This included Parent 7 who 
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described how: “we cried, me and [child’s name], when we had to give it back. We 
absolutely loved it… I absolutely feel gutted, absolutely gutted” and Adult 3 who 
reported how:  
 
“I was just generally frustrated. And I suppose that had an impact on my 
immediate family…so this week you know, I stopped yesterday. So over the 
past few days I have felt slightly grumpy because I didn’t want to give it up.” 
(Adult 3) 
 
Below, we begin by considering how (and why) participants benefited psychologically 
and emotionally from using a closed-loop. We also explore how participants had 
relaxed their diabetes management practices as a result of using this technology and 
become deskilled as a consequence. We do this because these kinds of experiences 
provide a vital context for understanding why loss of the closed-loop was 
experienced in physically and emotionally harmful ways. We also consider 
participants’ clinical and support needs at the end of the trial to help address the 
kinds of harms experienced. As all of our main findings cut across the sample, our 
reporting has not been separated out according to participant groups (e.g. adults, 
adolescents and parents); however, we do indicate when a particular issue was most 
keenly felt within one particular group. 
 




Participants described various overlapping psychological and emotional benefits to 
using the closed-loop, many of which only become fully apparent after they had 
direct experience of using the technology.  
 
Respite and less worry 
A central benefit, as participants noted, was that the closed-loop had enabled them 
to have respite from managing their (or their child’s) diabetes. This included Adult 3 
who likened her trial experiences to being “on a holiday” due to not having to 
constantly think about and make a conscious effort to keep her blood glucose levels 
within target ranges because the closed loop would “soak up” and address high and 
low blood glucose automatically:   
 
“it was great…it was like being on a holiday, where you can forget about your 
diabetes as much as possible, or just relax from it as much as possible. You 
know, it was nice to have a back-up that would…soak up all those extra blood 
sugars without me having to worry about it.” (Adult 3) 
 
Participants also described how they had worried less about hypoglycaemia (low 
blood glucose) while using the closed-loop due to system’s ability to detect when 
their (or their child’s) blood glucose was dropping and to suspend or reduce insulin 
delivery before their blood glucose went too low. This was highlighted as a particular 
benefit by parents, such as Parent 7, who described the closed-loop as having been 
“life changing” because, for the trial’s duration, they had been able to sleep at night 
without worrying about their pre-teenage child’s safety, such as the possibility of their 




“I absolutely loved it…I can only describe it for a parent, as life-changing, 
cause I mean in the night time it’s unreal. And I actually, I’d sleep the whole 
night, cause I trusted it…[because] if they [blood glucose levels] started to go 
low, it just literally…brought it all back up again. It was amazing. I didn’t want 
to give it back. (Parent 7) 
 
Improved relationships; less family conflict 
Participants also reported experiencing reduced conflict within their families due to 
improvements in their own mood resulting from experiencing more stable blood 
glucose levels, wherein, as Adult 3 observed. “I was just generally less grumpy 
because my bloods were in target more of the time… and so everyone else 
benefitted from that as well.” Parents also highlighted the benefits of not needing to 
constantly remind their child to undertake diabetes management tasks, such as 
frequent blood glucose testing, as this was done automatically by the continuous 
glucose monitor: 
 
 “there wasn’t so much, you know, stress I think all the time, to remind him 
(teenage son): have you done a sugar test? What’s happening with your 
sugars? I think all of that took a lot of pressure [off] our relationship, especially 
now…he’s becoming a teenager, and he doesn’t want to do a lot of things that 






Greater freedom and flexibility 
It was also noted how use of the closed-loop had enabled other aspects of everyday 
life to become more relaxed because participants had not needed to keep routines in 
place to remind them (or their child) to undertake blood glucose tests and, when 
necessary, to make adjustments to their or their child’s insulin. As a consequence, 
many, including Adult 8, reflected upon how they had allowed their lives to become 
more “complicated’” (for instance, by increasing their level of sporting and physical 
activities, and eating meals at more erratic times of days) during the trial:  
 
“you could allow your lifestyle to become complicated - because you didn’t 
need to make these sort of adjustments and corrections all the time. And so 
therefore if you didn’t have the closed loop you might have chosen to simplify 
certain things in your life so that you didn’t have those complexities.”  
(Adult 8) 
 
By virtue of the closed-loop’s ability to address falling blood glucose before it 
became too low, parents of pre-teenage children also noted having permitted their 
child to have more freedom, including allowing them, for the first time, to attend 
sleepovers at friends’ houses and school trips without their being present. Parents, 
such as Parent 7 also noted ensuing lifestyle benefits to themselves, such as being 
able to have nights out, because they had felt confident and able to leave child under 




“for the three months [of the trial] we had a break, we could anything- or she 
could do anything. We could even go out with (names friend) because people 
were happy to babysit and we were happy to let them.” (P7 parent). 
 
Similar benefits were also reported by adolescents and their parents who noted how, 
due to the closed-loop’s ability to keep their blood glucose stable, even if they forgot 
to administer insulin when they ate or consumed alcohol, there had been increased 
willingness to allow them to go out and attend parties and other social activities with 
peers:  
 
“I know for a fact that my mum and dad, say if was going out, they were happy 
to let me because I was wearing the closed loop and, if was planning to stay 
at my friend’s or whatever, they’d say: ‘oh well, put it on before you go 
because, you know, when you’re out you don’t want to be necessarily testing 
your blood.’ And my mum and dad, you know, they felt that I was safe with the 
closed loop on.” (Adolescent 1) 
 
Relaxing and loosing habits 
Participants also reflected upon how, as a result of having used a technology which 
had done a lot of the work on their behalf, they had become “lazy”, as Adult 10 put it, 
and had got out of the habit of undertaking key diabetes management practices, 
such as regular blood glucose testing, during the trial: 
 
“if you’re having to do that stuff a lot and [then] a computer is doing it all for 
you… the negative side is it probably has made me a little bit more lazy… And 
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I’m a little bit less in the habit, because I’m more used to looking at my CGM 
data and having that view of things rather than doing my own finger prick 
[blood glucose] tests” (Adult 10) 
 
“I felt that it changed my behaviour in terms of my diabetes. So it did make me 
relax, but I suppose not always in a good way. So, for instance, I tested my 
blood glucose levels less often than normal because the sensors were really 
accurate and it didn’t feel necessary.” (Adult 3) 
 
Deskilling  
In extreme cases, participants noted not only having got out of the habit of 
undertaking key diabetes management tasks, they also voiced concerns, now that 
their participation in the trial had come to an end, about having become deskilled. 
This included Parent 8 who noted how, after their child had reverted to their pre-trial 
regimen (an insulin pump), they realised that they had forgotten how to determine 
the size of the insulin dose they needed to administer to correct (bring down) high 
blood glucose:  
 
“The hardest part was actually going back at the end to just the pump, and 
remembering… I actually had to ask [child’s name] at one point. I was like: 
what do we do with this? (laughs) because I’d forgotten – like getting back into 






Adopting bad habits 
Due to the closed-loop’s perceived ability to automatically address small rises in 
blood glucose, many participants also noted how, as a result of using it they had also 
got into what were seen as “bad habits”, such as no longer administering insulin 
when they snacked: 
 
“And also in terms of little things like snacking that I wouldn’t be so vigilant 
about exactly how much carbohydrate I was having - so if I was preparing the 
kids’ tea I would just sort of like have a chip or two. Generally I would normally 
concentrate on exactly how many chips I was having and sort of have some 
insulin to go with it. But on the closed loop system I think I didn’t concentrate 
as hard because I assumed that the system would pick it up and would deal 
with the blood sugars that way round…that wasn’t a good habit to get into.” 
(Adult 3) 
 
Withdrawal of the closed-loop 
 
Addressing bad habits, relearning skills and reinstating old routines 
For all individuals, withdrawal of the closed-loop was also experienced as “a really 
big step back” (Adult 7). Specifically, participants described needing to make 
significant effort to address bad habits adopted during the trial, reinstate former 
routines and/or relearn how to undertake some of their former diabetes management 
tasks, wherein, as Adult 10 noted: “I’m having to step up the amount of management 
I do because, having got quite used to being quite relaxed about it, I now have to be 




“So I’ve got to try and retrain myself to make the decisions it was making for 
me…the only concerns really are the ones limited to my forgetfulness. And if I 
forget to bolus [take insulin] my sugars are going up, and I don’t have a 
sensor to warn me they’re going up. I’ve only got- I feel a bit ropey [unwell]. 
So then I’ll deal with it. And if I forget to bolus…I’ve not got anything covering 
my back. I’ve just got to do what I think’s right. Whereas the [closed-loop] 
actually made a lot of the smart decisions for you.” (Adult 9) 
 
Because of the amount of effort required to relearn key diabetes self-management 
skills and reinstate routines to remember to undertake diabetes-management tasks, 
some participants likened their post-trial experiences to being “a new parent again, 
because it’s like starting from the beginning, like we haven’t had diabetes before, 
cause we relied on the closed-loop so much” (Parent 4). Indeed, some, including 
Adult 10, noted how: “It’s… more of an adjustment to come back off it [closed-loop] 
than it is was to go on” because of the amount of time and effort required to reinstate 
their pre-trial diabetes management regimens.  
 
Increased motivation tempered by reverting to antiquated self-management tools  
Several participants also described how their experiences during the trial had given 
them a new impetus to better manage their, or their child’s, diabetes after the closed-
loop had been withdrawn. Specifically, some such participants, including Adolescent 
4 and Adult 6, described observing improvements in their blood glucose control while 
using the closed-loop, and feeling much better physically as a consequence, and, 




“So I’ve been doing my bloods like more regularly. So like I’m trying to keep it 
better controlled, just because I know… it feels much nicer when you do.” 
(Adolescent 4) 
 
“it’s probably inspired me to manage it a bit better cause I kind of think I can. I 
can have good blood sugars. Like normally after four months of being, having 
really good control, I’d probably just not bother at all for a few months. I’d test 
like once every other day, cause I’m like: I just need a break from it all. But 
actually I feel like: No. It’s worth making the effort and trying. So I’ve tested 
my blood sugar today twice already. (Adult 6) 
 
However, all such participants also noted the frustrations and anxieties arising from 
wanting to sustain better blood glucose control but of having to revert to using what 
they now saw as “old school methodology” (Adult 4) and antiquated technology, which 
Adolescent 5 noted, “feels like going from the latest i-phone to a brick phone.”  
 
As several individuals, including Adult 7, further reflected, use of this older and more 
basic technology simply could not permit them to attain the fine-tuned control they 
now wanted to achieve, leading them to feel a “loss of control” as a consequence: 
 
“I’ve experienced very high management of my diabetes. So, in contrast, you 
realise just how poor the amount of information you have to make decisions is 
when you don’t have CGM [continuous glucose monitoring]… So yeah. I 
guess those are the negatives… So… just having like a spot check of my 
22 
 
blood sugars … just looks, feels a bit one dimensional … after seeing… the 
whole sort of graph if you like of the CGM. So you kind of think: well, I’m not 
really getting a lot of information. You know, is my blood sugar going up or 
down? And eh, you don’t know that from a single measurement. So I guess, in 
a sense, I feel like I’m less in control.” (Adult 7) 
 
Potential physical harm 
Because of their new awareness of the limitations of their old regimens, and of the 
time and effort required to reinstate former habits and skills, participants also shared 
their anxieties and concerns that their or their child’s blood glucose control would be 
adversely affected post trial: 
 
“one of the risks is that somebody becomes very lazy. And becoming very lazy 
because you have the closed loop is fantastic if your closed-loop is going to be 
there all the time. But becoming very lazy and then you lose the closed-loop and 
then end up, you know, spending another three months trying to get your [child’s] 
sugars under control because you’ve now got out of the habit of tightly managing 
them.” (Parent 5) 
 
I know my HbA1c [average measure of blood glucose control] is going to 
change...I know it’s going to increase over the next three months…[because] 
there’s so much more that I need to get back into the way of doing things. Eh, I 
just hope that within, by at least three months from now, I will have a grasp of 




Psychological and emotional harms 
The emotional and psychological impact of having to step back into a life without the 
closed-loop was also widely discussed; an issue which is understandable given that, 
as described above, use of this technology had had such a positive impact on 
participants’ quality of life. Specifically, participants shared their worries and 
concerns about having to return to their more restricted (pre-trial) lives, characterised 
by family conflict, worry, strain and a more regimented way of living. This was 
especially the case for parents who shared the distress resulting from having to 
revert back to getting up several times during the night to make sure their child was 
not experiencing hyper or hypoglycaemia now they no longer had the back-up of the 
closed-loop:  
 
“So last night, I’ve been up all night. I’ve literally had three hours sleep. His 
sugars went high. Then I’m having to give him an adjustment, then having to 
wait. Whereas the artificial pancreas, the whole three months he had it, he 
had one hypo in the night… I actually thought: I can’t even believe that I’m 
having to go back to this after having- it was like luxury.” (Parent 9) 
  
Indeed, Parent 9’s implied grief was more explicitly articulated by others, including 
Parent 7, who likened their experience of losing the CLS to that of losing a family 
member:  
 
 “we need to get used to it again, not sleeping…. You get used to sleeping, 
and suddenly you aren’t sleeping again and (yawns) here we go again... We 
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just- we just really liked it, and really miss it now. So I think we feel like we lost 
a member of our family.” 
 
Adult and adolescents also highlighted the sense of loss and emotional distress. This 
included Adult 4, who described having been “so much happier when I was on it 
[closed-loop] because it took so much of the stress away of having diabetes” and 
noted how, they now felt like “a part of you is missing in some ways because, for me, 
using the closed-loop was life changing, so I really didn’t want to give it back.” 
 
When they reflected upon the emotional impact of returning the closed-loop at the 
end of the trial, some participants, including Parent 3, also noted how, by virtue of 
having had such positive experiences while using it, they now saw the life to which 
they (or their child) had to return much more negatively: 
  
“the study gave him a taste [of] what it feels like to have a working artificial 
pancreas… as with all the studies you know, you have that period where it’s 
all finished and you have to go back to how it was. And therefore it’s almost 
like taking a glimpse to what the future would look like. And then you go back 
again. And I think, you know, that is hard.” (Parent 3) 
 
Support received and needed at the end of the trial 
Virtually all participants indicated a need for support after completing the trial, with 
Adult 8, amongst others, noting that, had support from staff been abruptly withdrawn, 




“if my consultant said: right, thank you very much. Delete my number. Delete 
my email address. We aren’t having any more contact. That would not work. 
It- your- your sugars are going to go absolutely haywire afterwards.” 
 
Most individuals highlighted a need for clinical and educational input to help them 
relearn and reinstate pre-trial treatment regimens. However, some also indicated 
needing more holistic support, which comprised psychological as well as clinical 
elements. This was not only to help address anxieties and distress resulting from 
withdrawal of the closed-loop, but also to help them regain their confidence 
managing their or their child’s diabetes without the input of the closed-loop: 
 
“now I feel less confident. I just- last night was completely like I’m mind crazy. 
…there’s an email gone to (names hospital) two o’clock in the morning going: 
help me, as I just needed someone to reassure me that everything is going to 
be ok and that I am doing things right.” (Parent 7) 
 
While there was no protocol or ethically mandated requirement for trial staff to offer 
post-trial support, all participants described how staff had emphasised and reassured 
them of their on-going availability. However, it was also noted that, because this offer 
of post-trial support had been informal and unstructured, the onus had been placed 
on them to initiate contact (by email or phone) and “bother the doctor” (Adult 2) in the 




“they did say it [blood glucose levels] might for the first few days be a bit 
erratic.. but if I was quite worried to then just get in touch… and they’ll talk me 
through bits and pieces I can do.” (Adult 2) 
 
Hence, participants suggested that that future trial participants would benefit from 
more formal arrangements, whether this be a post-trial debriefing and education 
session as suggested by Parent 3 below, or, in Adult 7’s case, a series of contacts 
with staff to allow them time to optimise their blood glucose control using the pre-trial 
regimens to which they had had to revert: 
  
“a session with the team, where you would say…here’s the devices. Here’s 
everything back. Here is what we will suggest [you do with] your basal rates. 
But this is something to remind us now that you do need to do a little bit more 
testing and … that system is not there anymore for you.” (Parent 3) 
 
“I think it would quite useful to maybe get another one or two weeks with 
[health professional] contact...because the three months is quite a while. ...so 
having the extra assistance… even if it’s just for two weeks, you can get your 
sugars back into check.” (Adult 7) 
 
Discussion 
This study has offered an empirical window into an area of growing ethical attention 
and debate: whether individuals who take part in trials should be given opportunities 
to access post-trial care and what this care should comprise. In this study, which 
drew upon the perspectives and experiences of individuals (adults, adolescents and 
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parents) who had just completed a trial of an innovative technology to support 
management of type 1 diabetes, participants in all groups highlighted a need for 
post-trial care and support. In part, this support was seen as necessary to help 
circumvent potential physical harms (a deterioration in blood glucose control) arising 
from withdrawal of the closed-loop. Specifically, individuals described wanting and 
valuing education, training and practical support from trial staff to help reinstate the 
(forgotten) skills, habits and routines needed to undertake effective diabetes self-
management using the regimens to which they had to revert post-trial. Mirroring 
findings from other studies involving users of closed-loop systems, participants also 
described experiencing non-clinical benefits during the trial because the closed-loop 
had lessened the burden of diabetes management, permitted a more spontaneous 
and flexible lifestyle, and had reduced worry and enabled improved sleep, especially 
amongst parents (Barnard et al. 2014; Barnard et al. 2015; Hendrieckx et al. 2017). 
Hence, for these individuals, trial participation had unanticipated consequences for 
which they had felt ill-prepared and which had not been discussed in the participant 
information sheet (see above); namely, they had experienced a better (quality of) life 
which could not be sustained once the closed-loop had been withdrawn. Another 
unanticipated harm which some participants described was their re-evaluating their 
pre-and post-trial life in light of having used the technology, and now perceiving this 
life much more negatively. Others voiced frustrations about wanting to maintain the 
improvements in blood glucose control which had resulted from using the closed 
loop but of having to revert to using what they now saw as technologically imprecise 
self-management tools. Understandably, therefore, while participants were accepting 
of the requirement to return the closed-loop, virtually all described experiencing 
disappointment, anxiety and a sense of loss. In doing so, participants highlighted 
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both implicit and explicit needs for psychological and emotional support from staff. 
Hence, one contribution of this study is that it highlights the importance of debates 
about the provisioning of post-trial care being extended to trials of medical devices. 
We would also argue that these kinds of debates needs to be widened; specifically, 
that the kinds of harms considered in the ethical literature about post-trial care 
provisioning (e.g., Cook, Snyder, and Calvert 2016; Doval, Shirali, and Sinha 2015; 
Grady 2005; Milllum 2011) need to be broadened to consider potential emotional and 
psychological harms, and not just clinical harms, which may result from withdrawal of 
trialled treatments. 
 
In this study, participants did feel well supported by staff after trial completion and 
were grateful for their ongoing availability. However, because care arrangements 
had been informal and unstructured, individuals had felt the onus had been on them 
to initiate contact. This lack of formal post-trial support is unsurprising given that, as 
others have noted, even in situations where post-trial obligations have been seen to 
exist (e.g. WHO and CIOMS 2016, UNAIDS 2011), it often remains unclear with 
whom the moral and ethical duty to provide post-trial care (usually on-going access 
to drugs) resides (Doval, Shirali, and Sinha 2015; Grady 2005; Millum 2011; Sofaer 
et al. 2009; Pratt and Loff 2011). Commentators have also suggested that this 
responsibility should not fall upon the investigator team but, rather, should be 
cascaded to governments, sponsors and, in some cases, the international 
community (Millum 2011); indeed, the 2013 version of the Declaration of Helsinki 
acknowledges that the burden of providing post-trial access to treatment is far 
beyond the investigators’ scope (Palacios 2013). Commentators have also noted a 
lack of clarity about how post-trial care should be delivered to ensure ethical 
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responsibilities are met (Andanda and Wathuta 2017). This includes Cook et al. 
(2016) who, in a recent review of academic literature, legislation and international 
guidelines, note a distinct paucity of practical and tangible recommendations for 
addressing post-trial provisioning. As these authors further suggest, this tendency to 
make general rather than specific recommendations may serve to “mask the 
underlying challenges by providing cosmetic improvements to existing practices” 
(Cook et al 2016, 76). Pratt and Loff (2011) have raised similar concerns and, in 
doing so, have highlighted the dangers of macro-level obligations being allocated to 
micro-level actors. In keeping with these kinds of ethical concerns, others have noted 
how, in the absence of specific guidelines, resourcing and formal oversight, it has 
tended to fall to local investigators and front-line staff to creatively seek out 
temporary solutions to meet individuals’ post-trial needs, even though they have no 
formal ethical mandate to do so. This might include identifying additional research 
protocols in order to continue to provide participants with beneficial drugs (Grady 
2005) or, in the case of the current study, providing clinical, educational and 
emotional support to help individuals adjust to the loss of the closed-loop and 
reinstate pre-trial regimens. 
 
Although offers of post-trial support were appreciated by participants, other research 
suggests that individuals may be reluctant to initiate contact with health professionals 
due to their concerns that these individuals are already overstretched (Rankin et al. 
2012). In other words, when offers of health professional support are informal, 
participants may not always access the care they need. The impact on front-line staff 
also needs to be considered. As research undertaken with staff involved in the close-
out of another diabetes trial entailing withdraw of treatment (insulin pumps) has 
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served to highlight, ethical and emotional challenges at close-out may also extend to 
front-line staff (Lawton et al. 2017). In this study, staff reported feeling ill-prepared for 
close-out and, more specifically, for withdrawing treatment from patients who were 
anxious and distressed (Lawton et al. 2017). Staff also felt ill-equipped to provide 
patients with the emotional and psychological support some needed due to lack of 
resourcing and appropriate training. This study concluded that the close-out of trials 
involving withdraw of treatments/technologies should be subjected to the same level 
of ethical oversight as trial recruitment and delivery stages, a recommendation 
echoed by others who have also suggested that the remit of ethics committees 
should be broadened to help ensure ethically appropriate post-trial provisioning 
takes place (Andanda and Wathuta 2017; Grady 2005). As well as increased ethical 
oversight, staff working on future trials of medical devices might benefit from being 
given training and resourcing as part of their core trial funding to ensure they are 
able to give patients the support they need following treatment withdrawal. This 
might include input from psychologists, so that the kinds of emotional distress 
reported by participants in the current study, and noted by staff in the study where 
insulin pumps were withdrawn (Lawton et al. 2017), are handled appropriately. Our 
findings also suggest that, in order to help make informed decisions about their 
participation, individuals who are approached to take part in future trials might also 
benefit from being given information about potential (non-clinical) harms arising from 
withdrawal of treatment.  
 
While the current study raises important questions about what constitutes harm at 
the end of trials involving withdrawal of treatment, the specifics of the trial need to be 
taken into account. First, it needs to be considered that the trial’s investigated 
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technology was not commercially available; this made post-trial provisioning a moot 
issue as current regulations in the UK do not permit compassionate use (expanded 
access) to non-approved medical devices outwith a clinical trial. It should also be 
noted that, in comparison to individuals in third world and low income settings who 
might have to confront withdrawal of a potentially life-saving or sustaining treatment 
without an alternative treatment being made available, participants in the current 
study were able to return to a regimen which has been shown to be clinically 
effective (REPOSE Study Group 2017); hence it is likely that the kinds of emotional 
distress reported in this paper might be even greater in other kinds of settings and 
trials. The relatively short duration (three months) participants were in the trial should 
also be taken into account. While participants described their anxieties about having 
become deskilled as a result of using the closed-loop, it is likely that this deskilling 
and, hence, participants’ distress and need for post-trial support, would have been 
greater in a trial of longer duration. Others have also noted that, in long-term trials, 
participants may build up special relationships with researchers and, hence, they 
may experience termination of these relationships as a form of betrayal (Sofaer et al. 
2009). In other words, risks of emotional harm may not just arise from withdrawal of 
treatment but also from withdrawal of relationships forged during long-term trials. 
Empirical support for this suggestion can be found in a study in which individuals 
were interviewed after taking part in a diabetes trial which lasted over 20 years. 
These individuals described having forged close relationships with trial staff over the 
years and, hence, of having experienced a form of bereavement when the trial came 





As is typical in trials of technological innovations and medical devices (e.g. Polonsky 
and Hessler 2013; Ritholz et al. 2010), our sample was heavily skewed towards well-
educated individuals belonging to higher socio-economic groups and this potentially 
limits the generalisability of our findings. While we have provided an in-depth 
understanding of what the ethical issues are for trial participants when treatment (a 
medical device) is withdrawn at the end of the trial, our study would have been 
enhanced by longer-term follow-up of participants to establish the full implications of 
the emotional, psychological and physical harms they reported at trial close-out.   
 
Conclusion 
This article has reported findings from interviews undertaken with individuals who 
took part in a trial which sought to advance a technology which is intended to have a 
very direct and meaningful impact on the health and wellbeing of people affected by 
type 1 diabetes (Bekairi et al. 2018). Despite the beneficent nature of this trial being 
only too apparent, and the study undergoing all the required peer-review processes 
and ethical and research governance approvals, we have shown that there was 
potential for participants to experience (unanticipated) harms at the end of the trial by 
virtue of treatment withdrawal; albeit, it would appear that these harms were 
mitigated by local investigators offering informal, post-trial support. Not only does this 
study highlight the need for ethical consideration and debates to move beyond drugs 
trials undertaken in low income settings, we have also shown that, for these debates 
to be responsible, understandings of harm may need to be broadened to consider 
psychological and emotional harms, as well potential clinical harm, which may result 
from withdrawal of trial treatments. We have also suggested that, to help make 
33 
 
informed decisions about their participation, individuals might benefit from being 
given information about these kinds of non-clinical harms. 
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Table 1. Demographic characteristics of study participants  
 
 Participants 








     Male 








     13-17 
     18-65 
















    Professional 
    Semi-skilled 
    Manual 
    Higher Education  
    Secondary School 















*This includes: parents who represented children aged ≤12 years (n=5) and parents of children 
aged 13-15 (n=4).  In one instance, both parents of a child aged 13-15 participated in an interview.   
 
 
 
 
